UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 15, 2008

QUESTCOR PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in Charter)

California		001-14758		33-0476164
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)
3260 Whipple Road Union City, California				94587
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s telephone number, including area code: (510) 400-0700

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o		Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o		Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o		Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o		Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

     On May 15, 2008, Questcor Pharmaceuticals, Inc. (the “Company”), filed a Form 25 with the Securities and Exchange Commission (the “SEC”) announcing its voluntary delisting of all shares of its common stock from the American Stock Exchange (the “AMEX”). Simultaneously, the Company filed a Form 8/A with the SEC announcing its listing of all shares of its common stock with the NASDAQ.

     The Company’s last trading day with the AMEX was May 15, 2008, and the Company’s first trading day with the NASDAQ will be May 16, 2008, under the trading symbol “QCOR”.

Item 7.01. Regulation FD Disclosure.

     On May 16, 2008, the Company issued a press release announcing the new listing of the Company’s common stock on the NASDAQ under the trading symbol “QCOR”, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by this reference.

     The foregoing information is furnished pursuant to Item 7.01 and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d)

Exhibits.

Exhibit No.		Exhibit Description
99.1		Questcor Pharmaceuticals, Inc. Press Release dated May 16, 2008.

SIGNATURE

     Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EXHIBIT INDEX

Exhibit No.		Exhibit Description
99.1		Questcor Pharmaceuticals, Inc. Press Release dated May 16, 2008.

Exhibit 99.1

QUESTCOR TO COMMENCE TRADING ON NASDAQ TODAY
New Stock Symbol QCOR

Union City, CA — May 16, 2008 — Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced the company’s common stock will commence trading today, May 16, 2008, on The NASDAQ Capital Market under the stock symbol QCOR.

“Questcor is very pleased to join NASDAQ,” said Don Bailey, President and Chief Executive Officer of Questcor Pharmaceuticals. “Our objective is to provide added visibility to our investors, and we believe NASDAQ’s multiple market maker structure provides the largest liquidity pool and will enhance the exposure of our company’s stock. The NASDAQ Stock Market is recognized as the home of the world’s leading brands, with more shares trading on average per day than any other U.S. market.”

About Questcor

Questcor Pharmaceuticals, Inc. is a pharmaceutical company that owns two commercial products, H.P. Acthar^® Gel (“Acthar”) and Doral^®, and is developing new medications using strategies that generally require lower capital investment when compared to traditional development programs. Acthar (repository corticotropin injection) is an injectable drug that is approved for the treatment of certain disorders with an inflammatory component, including the treatment of exacerbations associated with multiple sclerosis (“MS”). In addition, Acthar is not indicated for, but is used in treating patients with infantile spasms (“IS”), a rare form of refractory childhood epilepsy, and opsoclonus myoclonus syndrome, a rare autoimmune-related childhood neurological disorder. Doral is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. The Company is also developing new medications, including QSC-001, a unique orally disintegrating tablet formulation of hydrocodone bitartrate and acetaminophen for the treatment of moderate to moderately severe pain. For more information, please visit www.questcor.com.

CONTACT INFORMATION:

Questcor Pharmaceuticals, Inc.
IR2@Questcor.com
Don Bailey
Steve Cartt
510-400-0700

EVC Group
Doug Sherk
Dahlia Bailey
415-896-6820